The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Affiliation
St Vincents University Healthcare Group, School of Medicine, University College, Dublin, Cardiology Department - Research Director, STOP-HF Unit
Country
Ireland
1. Current Status, Position
Mark Ledwidge is currently Research Director of the STOP-HF Unit in St Vincent’s University Healthcare Group, Dublin and UCD Professor (Adjunct) the School of Medicine, University College, Dublin.
2. Education
Mark studied pharmacy in Aberdeen, obtained a PhD in Pharmaceutics from Trinity College in 1997 and has worked as a pharmacist in community, hospital, industry and academia for almost 30 years.
3. Research Area
Major areas of interest include prevention of heart failure, heart failure therapeutics and pharmacogenomic strategies in heart failure.
4. Conflict of interest
Prof. Mark Ledwidge is:
• Funder, Researcher of Abbott Diagnostics
• Co-founder of Solvatrin Therapeutics
• Funded Researcher for :
• Novartis AG
• Bayer
• Hypercell